DMD and neuromuscular disease caused by qualitative or quantitative defects of dystrophin: Similarly, a concomitant reduction in dystrophin and any of the SGCs may illustrate the importance of considering coexisting dystrophinopathies in patients with sarcoglycan-deficient LGMD [9–13].